Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy
TL;DR
Imagine if scientists could take a small sample of your skin, turn those cells into the exact type of brain cells that are dying in ALS, and then test hundreds of potential medicines on them in a lab dish. That's essentially what this research accomplished. Scientists took skin cells from 100 people with ALS, converted them into motor neurons (the brain cells that control muscle movement), and discovered that these lab-grown neurons died in the same way as they do in actual ALS patients. When they tested over 100 drugs that had failed in human trials, 97% also failed in their lab model - proving their system works like the real disease. Most importantly, they found a combination of three drugs that kept the neurons alive longer, offering new hope for treatment.
Heterogeneous and predominantly sporadic neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), remain highly challenging to model. Patient-derived induced pluripotent stem cell (iPSC) technologies offer great promise for these diseases; however, large-scale studies demonstrating accelerated neurodegeneration in patients with sporadic disease are limited. Here we generated an iPSC library from 100 patients with sporadic ALS (SALS) and conducted population-wide phenotypic screening. Motor neurons derived from patients with SALS recapitulated key aspects of the disease, including reduced survival, accelerated neurite degeneration correlating with donor survival, transcriptional dysregulation and pharmacological rescue by riluzole. Screening of drugs previously tested in ALS clinical trials revealed that 97% failed to mitigate neurodegeneration, reflecting trial outcomes and validating the SALS model. Combinatorial testing of effective drugs identified baricitinib, memantine and riluzole as a promising therapeutic combination for SALS. These findings demonstrate that patient-derived iPSC models can recapitulate sporadic disease features, paving the way for a new generation of disease modeling and therapeutic discovery in ALS.
- 1Generated an iPSC library from 100 patients with sporadic ALS and demonstrated that motor neurons derived from these patients showed reduced survival and accelerated neurite degeneration compared to controls
- 2Screening of over 100 drugs previously tested in ALS clinical trials revealed that 97% failed to mitigate neurodegeneration in the SALS model, reflecting real clinical trial outcomes
- 3Identified a promising therapeutic combination of baricitinib, memantine and riluzole that significantly increased survival of SALS motor neurons
- 4Demonstrated that SALS motor neurons exhibited transcriptional dysregulation consistent with postmortem spinal cord tissues from ALS patients and showed pharmacological rescue by riluzole
- 5Established the first validated model of sporadic ALS using patient-derived iPSCs that recapitulates key disease features and correlates with donor survival
Single-minus gluon tree amplitudes are nonzero
Imagine tiny particles called gluons are like spinning tops. Their spin can be in one of two directions, which physicists call 'plus' or 'minus'. For decades, the rulebook seemed to say that you could never have a situation where just one gluon was spinning 'minus' and all the others were spinning 'plus' — that outcome was thought to be zero. This paper found a loophole. Under very specific, purely mathematical conditions that don't exist in our physical reality but are useful for calculations, this interaction can happen. The researchers wrote down the exact recipe for it, fixing a small but important detail in our fundamental rulebook for how the universe works.
Sub-part-per-trillion test of the Standard Model with atomic hydrogen
Scientists made an incredibly precise measurement of light emitted by hydrogen atoms that tested one of physics' most fundamental theories - the Standard Model - to an accuracy of 0.7 parts per trillion. This measurement also resolved a long-standing disagreement about the size of protons by confirming the smaller value found in previous experiments with exotic atoms.
Rock art from at least 67,800 years ago in Sulawesi
Imagine finding a spray-painted handprint on a cave wall. Over thousands of years, a thin, glassy layer of minerals, like limescale in a kettle, grew on top of it. Scientists used a high-tech laser to analyze that mineral layer. By measuring the natural radioactive decay of elements within it, they figured out the layer is about 71,600 years old. Since the handprint is underneath that layer, it must be at least that old, with the most conservative estimate being 67,800 years. This makes it one of the oldest pieces of art ever found and proves that the early humans who lived on this Indonesian island, who had to cross the ocean to get there, were creating symbolic art.
An interstellar energetic and non-aqueous pathway to peptide formation
Imagine you have a box of LEGO bricks, which are like the basic molecules of life called amino acids. To build anything, you need to snap them together. Scientists used to think you needed a puddle of liquid water to make the bricks 'click'. This experiment is like discovering you can snap the LEGOs together inside a freezer. The researchers took the simplest amino acid, froze it onto a dust grain like you'd find in space, and zapped it with energy that mimics cosmic radiation. They found that the amino acids linked up to form a two-brick chain, the first step towards building a protein. This means the essential first chains for life could be forming all over space and delivered to new planets by comets and asteroids.